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 Metabolic alterations in pregnant women: 
gestational diabetes 
 Abstract:  Gestational diabetes mellitus (GDM) and contro-
versy are old friends. The impact of GDM on maternal and 
fetal health has been increasingly recognized. Neverthe-
less, universal consensus on the diagnostic methods and 
thresholds has long been lacking. Published guidelines 
from major societies differ significantly from one another, 
with recommendations ranging from aggressive screen-
ing to no routine screening at all. As a result, real-world 
practice is equally varied. This article recaps the latest 
evidence-based recommendations for the diagnosis and 
classification of GDM. It reviews the current evidence base 
for intensive multidisciplinary treatment of GDM and pro-
vides recommendations for postpartum management to 
delay and/or prevent progression to type 2 diabetes. 
 Keywords:  diagnosis;  gestational diabetes;  metabolic 
alterations;  treatment. 
 Introduction 
 Gestational diabetes mellitus (GDM) is defined as glucose 
intolerance with onset or first recognition during preg-
nancy or as carbohydrate intolerance of variable sever-
ity diagnosed during pregnancy, which may or may not 
resolve afterward  (1) . The GDM increases the risk of compli-
cations for both mother and child during pregnancy, child-
birth, and beyond. Current evidence proposes that early 
detection and treatment of disease improve outcomes for 
both mother and child  (2) . The GDM is the most common 
metabolic complication during pregnancy associated with 
an increased risk of maternal (preeclampsia, hyperten-
sion, cesarean section) and neonatal death (macrosomia, 
birth injury, hypoglycemia, hyperbilirubinemia, hypocal-
cemia, respiratory distress syndrome)  (3) . The experience 
and clinical knowledge of potential risks is essential to 
provide adequate health care to both mother and baby  (4) . 
 The consensus on the classification established as a 
main groups: type 1 diabetes (T1D), type 2 diabetes (T2D), 
and GMD  (4) . 
 T1D is the classification established for insulin-depend-
ent diabetes associated with the  β cell ’ s autoimmune 
destruction of the islets cells of the pancreas, which leads to 
insulin deficiency. Markers are often found in the immune 
destruction of  β cells in the islets, including anti-islet cell, 
anti-insulin, and anti-glutamic acid decarboxylase. This type 
affects a young population (younger than 25 years)  (4, 5) . 
 T2D is the classification set for non-insulin-depend-
ent diabetes associated with insulin resistance. The mech-
anisms that lead to their appearance are insulin resistance 
and lack the progressive glucotoxicity insulin. Environ-
mental factors such as obesity, sedentary lifestyle, stress, 
and diet low in fiber and rich in unsaturated fats have an 
important role in these mechanisms. This occurs more 
often in obese adults (older than 35 years)  (4, 5) . 
 GDM is defined as glucose intolerance detected 
during pregnancy. This group of female patients requires 
further evaluation after pregnancy because this group 
may include patients not diagnosed with T2D in a previ-
ous pregnancy and pregnant women in whom the disease 
is detected during the third trimester of pregnancy, after 
a glucose tolerance test  (4) . This condition has evolved 
from a diagnosis related with metabolic risk T2D and with 
a clinical condition associated with increased risks for 
maternal and perinatal morbidity. T1D and T2D pre-preg-
nancy are associated with early and late complications 
in pregnancy, including metabolic complications of the 
newborn. Meanwhile, GDM is associated with complica-
tions in the second half of pregnancy, including also the 
metabolic complications of the newborn  (4) . 
 The ethnic composition of each population group 
has different rates of T1D and T2D patients. More than 
80 % of the population with diabetes in the world have 
T2D. Nordic European and Anglo-Saxon populations 
have higher rates of T1D. However, Hispanic, Asian, and 
African  populations exhibit higher rates of T2D  (4) . 
 The International Association of Diabetes and Preg-
nancy Study Group (IADPSG) recommends a 75-g oral 
glucose tolerance test (OGTT) between the 24th and the 
28th week of gestation for all women who were not pre-
viously diagnosed with diabetes by random testing or a 
fasting plasma glucose test in the first prenatal visit, with 
GDM diagnosed according to the IADPSG. The World Health 
Organization (WHO) protocol is more complete and simple: 
a glucose tolerance test between the 24th and the 28th week 
of gestation for all pregnant women exposed to the risk 
factors for GDM or abnormal fasting plasma glucose  (2) . 
 Under the aforementioned guidelines, all studies 
 recommend that all pregnant women with undiagnosed 
diabetes should undergo an OGTT between the 24th and 
the 28th week of gestation. However, the interpretation of 
the results is a significant change. Unlike the criteria of the 
WHO, the IADPSG guidelines state that an abnormal value 
after 1 h or after 2 h of fasting can be used for  diagnosis 
of GDM. However, it is suggested that an abnormal OGTT 
value after 1 h is sufficient. Additionally, unlike the guide-
lines of the American Diabetes Association (ADA), a single 
 abnormal value is suitable for the diagnosis of GDM  (6) . 
 Diabetes treatment in pregnant women is a continu-
ous medical challenge until now, although the prognosis 
has changed from the earlier times, when the only man-
agement was diet modification and maternal survival was 
unpredictable, to the time when insulin has become avail-
able as treatment and maternal survival is the rule, rather 
than the exception. 
 The diagnosis of GDM has cost implications. The 
largest expenditures occur when the number of diagnosed 
cases increases. The costs include the care provided by 
nurses, dietitians, and physicians, as well as regular moni-
toring of glucose and diabetes therapy  (7) . 
 Epidemiology 
 Despite the growing recognition of the impact of GDM on 
maternal and fetal health, the universal consensus on the 
diagnostic methods and parameters for the GDM are far 
from being achieved  (6) . 
 Although the carbohydrate intolerance usually disap-
pears after delivery, one-third of women affected remain 
with diabetes or altered glucose metabolism postpartum. 
It is estimated that 15 % – 50 % of women will develop dia-
betes in the coming decades after pregnancy  (8) . 
 The prevalence of GDM remains a matter of discus-
sion, although it is a common metabolic disorder during 
pregnancy. The prevalence in the general population 
is varied and may depend on the country of origin, the 
nature of the population, and the diagnostic criteria used 
 (3, 9) . Spanish and non-Caucasian women have a particu-
larly high risk for diabetes after GDM  (8) . 
 A current study from Canada showed that its inci-
dence is 3.3 %  (9) . GDM affects about 5 % of pregnant 
women in England and Wales annually  (10) . The preva-
lence of GDM in the USA is 5 % , reaching the limit of 14 % 
in high-risk populations, affecting about 135,000 women 
per year  (3, 9, 11) . 
 However, this fee may vary due to the differences in 
the method of data selection, low response rates, random 
selection of women, and lack of uniformity of the diagnos-
tic criteria in studies  (3) . 
 Risk factors 
 There are several factors that increase the risk of devel-
oping GDM. These factors are  (12) a previous diagnosis 
of GDM or prediabetes, decreased glucose tolerance, or 
a change in fasting plasma glucose; family history, i.e., 
first-degree relatives with T2D; maternal age, with the 
risk increasing with age (especially for women aged older 
than 35 years); ethnicity, with African-Americans, Afro-
Caribbeans, Native Americans, Hispanics, Pacific Island-
ers, and South Asians being at a greater risk for develop-
ing GDM; overweight, obesity, or severe obesity, which 
increases the risk of development of GDM in 2.1, 3.6, and 
8.6, respectively; excessive fetal growth, polyhydramnios, 
hypertension, or preeclampsia in the current pregnancy; 
children with a high birth weight in previous pregnancies 
( > 90th percentile or  > 4000 g); background obstetric fetal 
death, neonatal macrosomia, or GDM  (13) ; smoking, with 
women who smoke having twice the probability to develop 
GDM; polycystic ovary syndrome; and short stature  (14) . 
 However, about 40 % – 60 % of women with GDM are 
not exposed to any risk factor, and most show no symp-
toms; for these reasons, it is necessary to carry out screen-
ing on all pregnant women  (12) . 
 Metabolic alterations 
 During pregnancy, there are complex endocrine-metabolic 
adaptation processes, which include insulin sensitivity, 
increased  β -cell response, moderate increase in blood 
glucose levels, and change in free fatty acids (FFA) levels, 
triglycerides, cholesterol, and phospholipids. However, 
these changes do not induce a pathological condition; 
rather they reflect the necessary metabolic adaptation for 
the normal fetus development. These changes are also 
important to prepare the maternal organism for delivery 
and lactation. 
 In healthy pregnant women, glucose homeostasis is 
maintained despite insulin resistance through a compen-
satory increase in insulin secretion. This increase is asso-
ciated with a hypertrophy and hyperplasia of  β cells  (15) . 
 These changes are triggered and maintained by pla-
cental hormones. The maladjusted  β cell is likely to con-
tribute to the development of gestational diabetes. The 
inability to compensate for insulin resistance may reflect 
changes in intrinsic  β cells, such as glucokinase muta-
tions  (16) , or extrinsic mechanisms, such as an autoim-
mune process ( < 10 % )  (17) . However, most cases fail to rec-
ognize an identifiable cell change. In both GDM and T2D, 
intolerance to carbohydrates is developed when  β cell 
secretion is no longer sufficient to compensate for insulin 
resistance  (18) . 
 Besides the changes in glucose homeostasis, pregnant 
women with previous GDM are more prone to hypertension, 
hyperlipidemia, ECG changes, and mortality  (19) . In 1996, 
Meyers-Seifer and Vohr  (20) reported that total cholesterol, 
triglycerides, low-density lipoprotein (LDL) cholesterol, 
blood glucose, and systolic blood pressure were signifi-
cantly higher in women with GDM, suggesting a condition 
similar to metabolic syndrome that occurs in these women. 
 Glucose metabolism 
 Until the third month of pregnancy, fasting plasma 
glucose remains constant. Thereafter, the plasma 
glucose tends to decrease, 10 – 15 mg/dL, in the pre sence 
of increased concentration plasma insulin. Simultane-
ously, endogenous glucose production (EGP) is increased 
by 16 % – 30 %  (21) in order to meet the energy require-
ment. The increase in EGP is almost completely derived 
from gluconeogenesis. Similar to T2D, increased levels 
of circulating FFA may contribute to the supporting glu-
coneogenesis. However, while high plasma FFA levels 
may reduce glucose oxidation in T2D  (22) , during physi-
ological pregnancy, the latter is not reduced, rather it is 
increased  (23) . This suggests that active gluconeogenesis 
during pregnancy is likely to be the direct consequence 
of the hormonal profile rather than the changes in the 
metabolic environment. 
 Although the basal plasma glucose levels tend to 
decrease with the progression of pregnancy, the plasma 
glucose levels after meal ingestion are higher and with a 
longer durability due to impaired insulin-mediated glucose 
utilization, EGP suppression, and inadequate increase in 
first-phase insulin secretion. It is the exacerbation of these 
mechanisms that also leads to GDM. In these women, 
basal EGP increases similarly in patients with GDM and 
in control women throughout gestation. At the end of the 
pregnancy, insulin suppression of EGP is less effective in 
patients with GDM than in control subjects  (24) , possibly 
due to a more severe resistance of the liver to the suppres-
sive effect of insulin. Therefore, postprandial hypergly-
cemia is the most common initial abnormality of glucose 
homeostasis in GDM, due to the loss of early insulin 
release, thus contributing to the loss of glucose tolerance. 
The loss of first-phase insulin release is seen as a marker 
of the deterioration of the  β -cell function and as a defect 
in insulin secretion, which has been reported by a number 
of investigators  (25, 26) . When analyzed as a function of 
concomitant insulin action, a 67 % reduction in pancreatic 
 β -cell compensatory effect was found in women with GDM 
 (27) , as compared with normal pregnant women  (26) . 
 Insulin secretion 
 Insulin secretion increases continuously from the first 
until the third trimester of the pregnancy, where it reaches 
a maximum secretion, returning to normal after delivery, 
in both women with normal pregnancy and with GDM
  (24, 28) . The insulin response to the oral glucose ingestion 
is associated with a 120 % increase in first-phase insulin 
secretion by the 12th–14th gestational week. The second-
phase insulin secretion does not seem to be affected, 
at least in the first weeks of pregnancy  (29) . The absence 
of an increasing rapid phase of insulin secretion char-
acterizes the development of GDM  (24) . The insulin 
response after an intravenous glucose tolerance test is 
increased, compared with the values observed before 
and after  pregnancy, but in women with GDM, there is 
an unusual loss of first-phase insulin secretion  (29 – 31) . 
These observations are in accordance with the observed 
delay in the peak concentration of insulin after an oral 
glucose intake in GDM  (31) . 
 Lipid metabolism in GDM 
 During pregnancy, metabolic changes occur in the liver 
and the adipose tissue, which has a great impact on 
triglycerides, fatty acids, cholesterol, and phospholipids. 
After an initial reduction during the first 8 weeks of preg-
nancy, the plasma levels of lipids tend to increase. 
 Cholesterol is used in the placenta for the synthesis 
of steroid hormones, whereas fatty acids are oxidized and 
used for the synthesis of the cell membrane. Changes in 
total cholesterol leads to modifications in various lipopro-
tein fractions. High-density lipoprotein (HDL) cholesterol 
increases from the 12th week, due to an increase in estro-
gen, and remains high throughout the gestational period. 
The total and LDL-cholesterol levels progressively increase 
in the second trimester. A similar behavior occurs for the 
plasma levels of very low-density lipoprotein (VLDL) and 
triglycerides. The triglycerides are increased not only in 
VLDL but also in LDL and HDL. These changes are most 
likely explained by an increase in synthesis as well as a 
reduced clearance of triacylglycerol. It is very probable 
that the decrease in insulin sensitivity may also contribute 
to the increase in triglyceride concentration. An increase 
in VLDL-triacylglyrerols is associated with a fast transfer 
of triglycerides toward HDL by cholesterol ester transfer 
protein. Accordingly, the decreasing hepatic lipase activ-
ity leads to the formation of larger HDL particles, which 
are rich in triacylglycerols and have a low density  (32) . At 
the same time, LDL particles become richer in triacylgly-
cerols  (33, 34) , become smaller, and have a higher density. 
These specific changes may induce damage in pregnancy 
through the activation of atherogenesis. The lipid profile 
in GDM is similar to that accompanying insulin resist-
ance, such as in metabolic syndrome. Pregnant women 
with GDM have increased triacylglyrerol levels and low 
LDL-cholesterol levels, compared with healthy pregnant 
women. The FFAs in the circulation are also increased, a 
factor that contributes to insulin resistance, which con-
tributes to the development of fetal macrosomia as well, 
as they can pass through the placenta  (35) . 
 Women and fetus implications 
 The GDM is a risk to both the mother and the child. This 
risk is connected to high levels of glucose in the blood and 
potentiation of their consequences and can happen not 
only during pregnancy and birth but also during the life-
time of the mother and the child  (36) . 
 The Hyperglycaemia and Adverse Pregnancy 
Outcome (HAPO) study confirmed that 23,000 women 
from 15 different countries who have undiagnosed 
hyperglycemia during pregnancy are at an increased 
risk of giving birth to babies with macrosomia (fetal 
weight  > 4000 g), neonatal hyperinsulinemia (reflected 
in high levels of C-peptide in the umbilical cord), neo-
natal hypoglycemia, preeclampsia, and lesions at birth, 
including fractures and nerve paralysis  (1, 9) . Mac-
rosomia may affect 12 % of normal pregnant women, as 
compared with 20 % of pregnant women with GDM  (1) . 
The pathological mechanism of GDM leads to complica-
tions known as the Pedersen hypothesis. The Pedersen 
hypothesis states that high maternal glucose leads 
to increased glucose transport across the placenta. 
The fetal pancreas responds to the glucose load, thus 
increasing insulin secretion. Fetal hyperinsulinemia 
leads to an extreme fetal growth, as the insulin acts as 
a growth factor. After birth, fetal hyperinsulinemia may 
continue for some time, increasing the risk of neonatal 
hypoglycemia, and this may require monitoring of neo-
natal blood glucose levels and other interventions to 
reverse the hypoglycemia  (1, 6, 9) . 
 The long-term complications for babies whose 
mothers have experienced GDM include twice the risk of 
developing childhood obesity and an increased risk of 
developing T2D in adulthood  (9) . 
 The HAPO study established the association between 
GDM and several adverse outcomes, including excess 
birth weight, cesarean section, neonatal hypoglycemia, 
shoulder dystocia, birth injury, preeclampsia, premature 
delivery, and neonatal hyperbilirubinemia  (9) . 
 When GDM is controlled with diet, exercise, and mon-
itoring of glucose levels, the risk of complications at birth 
is significantly reduced. The traditional setting of GDM 
involves women without previous knowledge of diabetes, 
particularly T2D. The results of T2D in pregnancy are as 
bad, if not worse, as those in T1D. These poor outcomes 
include high rates of birth defects and perinatal death  (1) . 
 Pregnant women with GDM often develop long-term 
T2D, as GDM masks the  β cells ’ failure to compensate for 
insulin resistance during pregnancy  (1) . 
 A preconception blood glucose analysis is rec-
ommended for women with a history of GDM, as the 
probability of disease recurrence is between 30 % and 
50 %  (37) . These women should be advised to perform 
blood glucose tests at the beginning of future pregnan-
cies, pre ferably around the 16th and 18th week of gesta-
tion  (9) . 
 Diagnosis 
 The diagnosis of GDM involves two distinct temporal 
phases: fasting glucose at the first prenatal surveillance 
visit (screening) and OGTT. This test is recommended 
by the WHO and the ADA and must be applied in a 
standardized manner to minimize variability. Accord-
ing to the WHO norms, the test should be performed 
between the 24th and 28th week of gestation. However, 
if pregnant women have some risk factors and/or have 
a positive screening test, tolerance test may be done 
sooner  (37, 38) . 
 Fasting plasma glucose at the first prenatal 
surveillance visit 
 A fasting plasma glucose test must be performed on all 
pregnant women during their first surveillance visit. The 
value obtained should be interpreted as follows: (i) a 
fasting plasma glucose value of  < 92 mg/dL (5.1 mmol/L) 
is considered normal but should be followed by an OGTT 
with an overload of 75 g glucose between the 24th and the 
28th week of gestation; (ii) a fasting plasma glucose level 
between   ≥  92 mg/dL (5.1 mmol/L) and  < 126 mg/dL (7.0 
mmol/L) indicates a positive diagnosis of DGM and it is not 
necessary to perform OGTT with 75 g of glucose between 
the 24th and the 28th week of gestation; and (iii) a fasting 
plasma glucose value   ≥  126 mg/dL (7 mmol/L) or a casual 
plasma glucose value  > 200 mg/dL (11.1 mmol/L) indicates 
probable diabetes before pregnancy and is first diagnosed 
in the current pregnancy. This value should be confirmed 
on a second occasion, on a different day, with another or 
a casual plasma glucose fasting glucose. These pregnant 
women should be treated and followed-up as women with 
prediabetes. According to current WHO recommenda-
tions, an HbA1c value   ≥  6.5 % should be interpreted as a 
diagnostic criterion for probable diabetes. However, this 
test should not be included among those performed in the 
surveillance of low-risk pregnancies  (37) . 
 Oral glucose tolerance test 
 OGTT should be performed on all pregnant women, 
excluding those who have been previously diagnosed 
with GDM or probable prediabetes. OGTT is preceded by 
3 days of regular exercise and a non-restrictive diet con-
taining 150 g carbohydrates daily. Glucose (75 g, diluted in 
300 mL of water) is orally taken in the morning after a fast 
of at least 8 h but not exceeding 14 h, with blood glucose 
determinations at 0, 1, and 2 h. During the test, the woman 
should remain at rest. The diagnosis of GDM is obtained 
when one or more values are greater than or equal to the 
reference values reported in Table  1 . 
 If the result of the OGTT is below the reference 
values described in the table, the test is considered neg-
ative. According to the recommendations, OGTT should 
not be routinely performed before the 24th and the 28th 
week of gestation because of the lack of consistency 
among the results during in this period. The current 
GDM diagnosis scheme does not consider a repeated 
OGTT in third trimester of pregnancy. Pregnant women 
who only begin surveillance pregnancy after the 28th 
week should undergo the test using the new diagnostic 
strategy of GDM: first perform fasting plasma glucose 
and if it is  < 92 mg/dL (5.1 mmol/L), perform an OGTT 
loaded with 75 g of glucose  (37) . 
 Treatment 
 The main goal of the GDM ’ s treatment is to keep the blood 
glucose controlled, leading to improvements in preg-
nancy, such as reductions in macrosomia, clinical neona-
tal hypoglycemia, and cesarean section rates. 
 Non-pharmacological treatment 
 Most pregnant women with GDM can successfully control 
blood glucose levels through lifestyle changes and by fol-
lowing a diet and exercise plan. 
 Diet and nutrition 
 Pregnant women with a diagnosis of GDM should be 
directed to a nutritionist; their sugar consumption should 
be decreased, while lean protein and vegetable consump-
tion should be increased. The nutritional recommenda-
tions for pregnant women with GDM are different from the 
recommendations for non-pregnant women with DGM, 
Fasting plasma glucose
Normal   <  92 mg/dL (5.1 mmol/L)
GDM    ≥   92 mg/dL (5.1 mmol/L)
  <  126 mg/dL (7.0 mmol/L)
Treated as prediabetes    ≥   126 mg/dL (7 mmol/L)
  >  200 mg/dL (11.1 mmol/L) occasional
HbA1c    ≥   6.5 % a 
 Table 1   Fasting plasma glucose: normal, GDM, and prediabetes 
reference values. 
 a This examination is not included in the surveillance test of 
pregnancy. 
as the diet of pregnant women with GDM contains more 
protein and fat. In pregnant women with GDM, 75 % – 80 % 
are able to maintain normal levels of glucose through 
dietary changes. 
 Caloric distribution 
 For caloric distribution, most of the programs suggest 
three meals and three snacks, distributed throughout 
the day. However, in pregnant patients with obesity or 
overweight, snacks are eliminated. The recommended 
daily caloric distribution is as follows: breakfast, approxi-
mately 10 % of the total calories assigned (because insulin 
resistance is higher in the morning); lunch, about 30 % of 
calories; dinner, no more than 30 % of calories. Snacks 
throughout the day should represent 30 % of calories. The 
caloric recommendations by nutrient is that major diet 
components should be fats ( ∼ 40 % ) and carbohydrates 
( ∼ 40 % ) followed by proteins (20 % )  (37) . 
 Physical exercise 
 The main ojective of exercise in the GDM to decrease 
glucose intolerance through cardiovascular conditioning, 
which causes an increase in the affinity of insulin to its 
receptor by decreasing intra-abdominal fat, an increase 
in glucose transporter sensitivity to insulin on muscle, 
an increase in blood flow in insulin-sensitive tissues, and 
a decrease in FFA levels  (37, 39) . Moderate physical exer-
cise (1 h per day) is recommended to all pregnant women. 
However, the intensity and type of exercises should be 
adapted to avoid security problems for pregnant women. 
 Glucose monitoring in pregnant women at home 
 Pregnant women should be asked to report the results of 
their glucose measurements after 1 week of monitoring at 
home and every 2 – 3 weeks until delivery. Pregnant women 
should be informed if there are changes to their treatment 
based on these results  (39) (Table 2) . 
 Pharmacologic treatment 
 Pharmacological treatment is initiated when the 
changes in lifestyle are not enough to achieve accept-
able levels of glucose. However, the glucose level at 
which the benefits of pharmacotherapy clearly out-
weigh its disadvantages or harm has not yet been clearly 
established. 
 Older recommendations such as those from the Ameri-
can College of Obstetricians and Gynecologists in 2001 
suggest that pharmacotherapy should be initiated when 
fasting plasma glucose is   ≥  95 mg/dL, 1-h postprandial 
plasma glucose is   ≥  130 – 140 mg/dL, or 2-h postprandial 
plasma glucose is   ≥  120 mg/dL  (39, 40) . 
 Insulin therapy 
 There are many forms of insulin to treat diabetes. How 
fast they start to work and how long their effects last 
 classify them in rapid acting (insulin lispro, insulin 
aspart and insulin glulisine), short acting (regular 
insulin),  intermediate acting (NPH insulin) and long 
acting (insulin glargine, insulin detemir). Insulin lispro, 
which is analogous to human insulin (peaking action 
after an hour of injection), has been shown safe during 
pregnancy, with no significant increase in birth defects, 
and significantly improving the postprandial glycemic 
control and long-term glycosylated hemoglobin. However, 
there are no  differences in relation to the regular insulin 
and perinatal outcome  (39) . 
 Prevention 
 Women with GDM have a 70 % higher incidence of T2D 
than the rest of the population. Depending on ethnicity, 
the rate of progression of GDM to T2D ranges from 50 % to 
70 % over 5 – 10 years of follow-up. Consequently, the con-
tinuous monitoring and annual screening for the detec-
tion of diabetes is important because it means the preven-
tion of the disease  (10) . 
 Preconception care is crucial when planning to 
become pregnant, and women must pay close attention 
to their blood glucose levels  (37) . Pregnant women diag-
nosed with GDM should be encouraged to practice a better 
lifestyle by increasing their physical activity, haing better 
eating habits, and maintaining ideal body weight. These 
women should be advised to perform tests for diabetes 
every 1 – 3 years  (9, 41) . 
Time, h Plasma glucose
0   <  92 mg/dL (5.1 mmol/L)
1    ≥   180 mg/dL (10.0 mmol/L)
2    ≥   153 mg/dL (8.5 mmol/L)
 Table 2   Plasma glucose levels at different times. 
 Recent data from the Diabetes Prevention Program 
suggest that lifestyle interventions are equally effective 
in reducing the risk of progression to T2D, approximately 
50 %  (10) . 
 In the long term, the ADA recommends that women 
with GDM in a previous pregnancy should screen for 
diabetes every 3 years after obtaining normal post-
partum results and annually if postpartum results are 
high. 
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